You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

Claims for Patent: 5,786,213

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,786,213

Title:	Inhibition of endogenous gastrin expression for treatment of colorectal cancer
Abstract:	The present invention discloses is for the treatment of colon cancer. The expression of gastrin by colon cancers is inhibited by the use of antisense gastrin expression. Methods are disclosed for the preparation of expression constructs and the use of such constructs to inhibit colon cancer growth.
Inventor(s):	Singh; Pomila (Galveston, TX), Wood; Thomas G. (Houston, TX)
Assignee:	Board of Regents, The University of Texas System (Austin, TX)
Application Number:	08/634,546
Patent Claims:	1. An isolated genetic construct comprising an antisense polynucleotide sequence of SEQ ID NO:1 flanked by SEQ ID NO:3 at the 5' end, and by SEQ ID NO:4 at the 3' end, wherein transfection in vitro of gastrin-producing human colon cancer cells by a vector comprising said isolated genetic construct results in reduced expression of gastrin gene products. 2. The isolated genetic construct of claim 1 defined further as inhibiting the growth of human colon cancer cells. 3. The isolated genetic construct of claim 1 defined further as comprising a promotor. 4. The isolated genetic construct of claim 1 defined further as including a vector. 5. The isolated genetic construct of claim 1 defined further as comprising a viral vector. 6. The isolated genetic construct of claim 1 defined further as comprising a retroviral vector. 7. The isolated genetic construct of claim 1 defined further as comprising an adenoviral vector or an adeno-associated viral vector. 8. The isolated genetic construct of claim 1 defined further as including a promotor from CMV, LTR or SV40. 9. The isolated genetic construct of claim 1 defined further as including a segment within 50-200 bases of an intron/exon splice junction.

Details for Patent 5,786,213

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.